Intarcia Therapeutics is well on its way to securing $600 million in financing. The company recently posted $215 million in a new round of financing and is on its way to seeking regulatory approval for its matchstick-sized diabetes therapeutic platform, ITCA-650.
Novo Nordisk’s experimental injectable diabetes drug semaglutide reduced cardiovascular risk by 26 percent, paving the way for a bigger study on the drug’s benefits.
While acknowledging the many complexities of product development, sponsor teams should factor in these six guiding principles when planning programs for regulatory submission.
Shares of Novavax plummeted more than 82 percent after the company released data that its Phase III trial for its RSV F Vaccine for older adults did not meet its goals, failing to demonstrate “vaccine efficacy.”
A roundtable of experts discuss what is the single most imperative thing marketers understand about the unique measurability and data-driven targeting that is possible within point of care.
The U.S. FDA approved a pill that combines aspirin and the acid-fighting drug omeprazole to guard against gastric ulcers in patients who require daily aspirin.
Partnership for Drug-Free Kids Announces National Launch of “Search and Rescue” Opioid Prescriber Education Campaign
Partnership for Drug-Free Kids announced the national launch of “Search and Rescue,” a prescriber education campaign that gives healthcare providers the resources they need to prescribe opioids responsibly and prevent the misuse and abuse of medicine in their practices.
In light of its August 30 announcement that its fostamatinib met its primary endpoints in two Phase III clinical trials, Rigel Pharmaceuticals reported that it will undergo major restructuring as it shifts from a research-and-discovery company to a commercial organization.
Teva Pharmaceutical Industries Ltd. said it was collaborating with Intel Corp. to develop a wearable device to monitor patients with Huntington’s, a fatal degenerative disease.
Shire Inc. recently launched Xiidra, the first medicine indicated for the signs and symptoms of dry eye disease and the company’s first ophthalmic drug.
AcelRx Pharmaceuticals Inc. said its experimental opioid painkiller was well tolerated in post-operative patients in a late-stage study.
Eisai Inc., the U.S. subsidiary of Japan’s Eisai Co. Ltd., announced that it is launching a research-and-discovery unit in the Boston area to focus on Alzheimer’s, cancer and autoimmune diseases. The new unit will be called the Eisai Andover Innovative Medicines (AiM) Institute and will be located in Andover, Mass.
GlaxoSmithKline’s experimental vaccine to prevent the intensely painful condition known as shingles remained 90 percent effective in people over age 70 even four years after receiving the injection, according to published data.
Aerie Pharmaceuticals Inc. said its eye drug met the main goal in a late-stage study, sending the company’s shares up 71 percent in extended trading.
Mylan NL Chief Executive Officer Heather Bresch will appear at a Sept. 21 congressional hearing over price increases for its allergy auto-injector EpiPen, the U.S. House of Representatives Oversight Committee said in a statement.
Allergan plc will acquire Vitae Pharmaceuticals Inc. for $21.00 per share, in cash, for a total transaction value of approximately $639 million.
Shire Plc said the U.S. FDA approved its treatment for patients with primary immunodeficiency, a group of genetic disorders.
The world cannot rely solely on free markets to deliver medicines needed by billions of people in poor countries, so governments should commit to a legally binding convention to coordinate and fund research and development. That is the conclusion of a major United Nations report, which is bound to stir fierce debate between supporters of the current market-based system of drug development and those favoring a greater role for the state.
An experimental stem cell therapy developed by Asterias Biotherapeutics restored some movement to patients paralyzed by recent spinal cord injuries, according to interim data from a small study.
Takeda is on the prowl and looking for big game. The company has set aside $15 billion to go after U.S. pharmaceutical acquisitions in an effort to reduce its dependency on the Japanese domestic market, which has been sluggish of late, Reuters reported.